Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24530802 | 0.80 | CRBN (0.40) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL13678434 | 0.80 | CRBN (0.40) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL12396073 | 0.76 | — | — | |
| SCHEMBL17884541 | 0.68 | CRBN (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL3628061 | 0.67 | — | — | |
| SCHEMBL19370773 | 0.67 | — | — | |
| SCHEMBL493044 | 0.67 | — | — | |
| SCHEMBL22166575 | 0.67 | — | — | |
| SCHEMBL528253 | 0.67 | — | — | |
| SCHEMBL8030518 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957056-B2 | Migrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTIUTE FOR CANCER RESEARCH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8835693-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-09-16 | — | — | US | disclosed |
| EP-1805161-B1 | ISOMIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER | SLOAN KETTERING INST CANCER (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140011844-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-01-09 | — | — | US | disclosed |
| US-8324284-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-04 | — | — | US | disclosed |
| US-8202911-B2 | Migrastatin analog compositions and uses thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8188141-B2 | Isomigrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110263653-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-27 | — | — | US | disclosed |
| US-7943800-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
| EP-1805161-A2 | ISOMIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER | Sloan-Kettering Institute For Cancer Research (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070037852-A1 | Migrastatin analogs and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-15 | — | — | US | disclosed |
| US-20070037783-A1 | Migrastatin analogs and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-15 | — | — | US | disclosed |
| WO-2006034478-A2 | ISOMIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1613603-A2 | MIGRASTATIN ANALOGS AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2006001967-A2 | MIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1608626-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087672-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087673-A2 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037783-A1 | Migrastatin analogs and uses thereof | FOXM1, MTX1, C3AR1 | CRBN 3154/4885DDB1 4771/4885ALDH1A1 1571/4885 |
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | EDNRB, KDR, IGF1R | CRBN 2678/4885DDB1 3573/4885ALDH1A1 1703/4885 |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | KDR, HMGCR, LPAR3 | CRBN 2072/4885DDB1 4207/4885ALDH1A1 1123/4885 |
| US-20110263653-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | C3AR1, C1R, MRPS18A | CRBN 2992/4885DDB1 4746/4885ALDH1A1 1845/4885 |
| US-20070037852-A1 | Migrastatin analogs and uses thereof | KDR, MTX1, FOXM1 | CRBN 2312/4885DDB1 4193/4885ALDH1A1 1124/4885 |
| US-20140011844-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | KDR, HMGCR, LPAR3 | CRBN 2072/4885DDB1 4207/4885ALDH1A1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.